Evaluation of chemotherapeutic regimen and associated adverse drug reactions of colorectal cancer in a tertiary care hospital

Background: Colorectal cancer (CRC) is the fourth most common cause of death diagnosed in both men and women. Though there are modifiable and non-modifiable risk factors for CRC. cancer patients encounter chemotherapy- associated drug interactions and adverse drug reactions hence the need for such a study will help the professionals to improve the patient’s quality of life. Materials and Methods: A six-month retrospective study of 130 patients who satisfied the inclusion and exclusion criteria was conducted by collecting data from November 2020 to May 2021. Data was collected from the Mediware system of the hospital using specially designed data collection forms. Results: Out of 130 patients, 61.51% were male and most of the patients were more than 60 years old. In this study, 11 patients had a history of smoking and alcoholism and 4% had a family history of CRC. Comorbidities associated with CRC were HTN and DM. In the study, stage 4 cancer patients were found to be more. 77.69% of patients had received chemotherapy along with surgery, and the most commonly prescribed regimen was Capcetabine and OxaliplatinThe length of hospital stay was increased for the FOLFOX (Oxaliplatin, 5-Fluorouracil, and Leucovorin) regimen. The common ADR analyzed was constipation, followed by vomiting and neutropenia, and most ADRs were associated with the CAPOX regimen (diarrhea) and treated accordingly.10 patients had febrile neutropenia, 5 patients had grade 4 neutropenia and all were treated with antibiotics and filgrastim. Febrile neutropenia was seen in patients with metastasis. Conclusion: Timely and appropriate treatment for ADRs and early screening can improve the quality of life of individuals. Further studies on this topic will help to improve the treatment quality provided by professionals

Therapeutic observation and pharmacoeconomic analysis of two first-line chemo-therapy regimens in advanced NSCLC / 药学实践杂志

Objective To evaluate the cost-effectiveness of two chemotherapy regimens in NSCLC for the purpose of lower cost,higher quality medical care.Methods 56 patients with advanced NSCLC were divided into two groups from our hospital,group PP(pemtrexal+cisplatin,n=30)and group GP(gemcitabine+cisplatin,n=26),and analyzed by pharmaco-economic cost-effectiveness method,and retrospective analysis was also applied.Results Effective rates of two regimens were 46.67%,42.31%,no significant difference.But there was significant difference in the incidence rate of ADR between the two groups.The cost of chemotherapy regiments were 31 985.48 and 27 683.15 yuan.The average length of stay was 10.94 and 13·91 days.Compared to group GP,for each unit of efficacy,the cost in group PP were increased 986.77 yuan.Conclusion From the analysis of cost-effectiveness,group PP had higher chemotherapy costs,but better safety than group GP.

The therapeutic improvement of pediatric acute myeloid leukemia / 国际儿科学杂志

Acute myeloid leukemia(AML) is a heterogeneous kind of disease,which is accounting for 15％ ～ 20％ of all tumors diagnosed in children under 15 years of age.In the past few decades,remarkable improvements have been yielded in long-term outcomes for children with AML.A better risk-group stratification of disease,which is based on clinical and biological features,a more effective use of anti-leukemia agents and enormous improvements in supportive care have increased the rate of cure by approximately 60％.This paper review the new improvements in the chemotherapeutic regimens and drugs.